Alliance pancanadienne pharmaceutique (APP) – dernières mises à jour
| État | Nombre total | Résumé |
|---|---|---|
| Négociations actives | 28 | Non liées à l’oncologie: 12 Liées à l’oncologie: 16 |
| Négociations envisagées | 35 | Non liées à l’oncologie: 26 Liées à l’oncologie: 9 |
| Négociations terminées | 707 | Avec lettre d’intention: 606 Sans entente: 101 |
| Négociations qui n’ont pas eu lieu | 104 |
Activités de l’APP dans les quatre dernières semaines
Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.
Lettres d’engagement transmises au cours des quatre dernières semaines
| Marque | Fabricant | Indication | Date d’engagement |
|---|---|---|---|
| Polivy | HOFFMANN-LA ROCHE LIMITED | Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherw | |
| Jardiance | Boehringer Ingelheim (Canada) Ltd. | adjunct to standard of care therapy for the treatment of chronic heart failure in adults | |
| Vectibix | Amgen Canada Inc. | In combination with chemotherapy, for the first-line treatment of mCRC patients with left-sided primary tumours that express wild-type RAS. | |
| Jemperli | GlaxoSmithKline Inc. | Jemperli (dostarlimab for injection) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial ca | |
| Akeega | Janssen Inc. | Akeega is indicated with prednisone or prednisolone for: The treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC), who are asymptomatic/mildly | |
| Amvuttra | Alnylam Netherlands B.V. | Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) | |
| Opdivo | Bristol Myers Squibb Canada Inc. | Cabometyx in combination with nivolumab for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC. | |
| Rezurock | sanofi-aventis Canada Inc. | For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. |